Table 4:
Clinical value of intraoperative near-infrared imaging.
| Patient | Procedure | Final Pathology | Benefit of Imaging | Potential Operative Changes Based on NIR Imaging |
|---|---|---|---|---|
| 1 | PD | PDAC | Identified positive margin | Abort resection Consider preoperative therapy |
| 2 | ODP | PDAC | Identified positive margin | Abort resection Consider preoperative therapy |
| 3 | PD | Intrapancreatic cholangiocarcinoma | Identified positive margin | -- |
| 4 | LDP | PDAC | Tumor localization Margin assessment |
-- |
| 5 | PD | PDAC | Margin assessment | -- |
| 6 | ODP | IPMN | Tumor localization | -- |
| 7 | PD | PDAC | Identified positive margin | Abort resection Consider preoperative therapy |
| 8 | PD | Neuroendocrine tumor | -- | -- |
| 9 | LDP | Microcystic serous cystadenoma | Tumor localization | -- |
| 10 | ODP | PDAC, 10% viable tumor | Predicted good response to neoadjuvant therapy | -- |
| 11 | ODP | PDAC | Margin assessment | -- |
| 12 | ODP | IPMN | Tumor localization | -- |
| 13 | TP | PDAC, 100% viable tumor | Predicted poor response to neoadjuvant therapy | Abort high-risk resection entirely |
| 14 | LDP | Neurofibroma | Predicted benign pathology | -- |
| 15 | PD | IPMN | Predicted benign pathology | -- |
| 16 | Appleby | PDAC, 100% viable tumor | Predicted treatment response Identified positive margin |
Abort high-risk resection entirely |
| 17 | PD | PDAC | Margin assessment | -- |
| 18 | PD | Serous cystadenoma | Predicted benign pathology | -- |
| 19 | PD | PDAC, 100% viable tumor | Predicted poor response to neoadjuvant therapy | Abort high-risk resection entirely |
| 20 | ODP | Neuroendocrine tumor | -- | -- |
Abbreviations: NIR near-infrared, PD pancreaticoduodenectomy, PDAC pancreatic ductal adenocarcinoma, ODP open distal pancreatectomy, LDP laparoscopic distal pancreatectomy, IPMN intraductal papillary mucinous neoplasm, TP total pancreatectomy.